Biohaven gets FDA priority review for neuro disease drug after refuse-to-file

Biohaven's experimental drug troriluzole for the rare, neurodegenerative disease spinocerebellar ataxia will get a priority review from the FDA, after the company presented additional real-world data. The Connecticut-based biotech said Tuesday that an FDA decision ...